Salix Pharmaceuticals to Acquire Santarus

Solidifies Position as Largest U.S. Gastroenterology-Focused Specialty Pharmaceutical Company
Provides Salix with an Experienced Specialty Sales Force to Significantly Expand Gastrointestinal Product Sales
Increases Commercial Presence in Gastroenterology, Hepatology and Colorectal Surgery
Estimated 2013 Pro Forma Total Product Revenue of $1.3 Billion
Greatly Increases Scale and Revenue Diversification
Expected to be Immediately and Significantly Accretive
Expected to Generate Strong EBITDA and Cash from Operations
Leading to Rapid Debt Repayment

Salix Pharmaceuticals, Ltd. (SLXP) and Santarus, Inc. (SNTS) today announced that the companies have entered into a definitive merger agreement under which Salix will acquire all of the outstanding common stock of Santarus for $32.00 per share in cash (without interest).

Advanced Proteome Therapeutics Corporation Advances Anti-Cancer Program

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) is pleased to announce the achievement of an important milestone in its anti-cancer program with its collaborators by demonstrating that the first of a series of the Company's site-specifically labeled protein conjugates binds tightly to specific tumor cells and concentrates in tumor tissue, when administered intravenously, in animals. We have also demonstrated that the protein itself retards the growth of established tumors in animals. These results provide a basis for augmenting the protein's fundamental anti-cancer activity with additional entities, such as chemotherapeutics and/or other targeting entities. In addition, initial studies indicate that the Company has discovered a novel method for substantially increasing the affinity of the protein toward such cancer cells, with potential for yielding superior, first in its class, anti-cancer therapeutics.

Endocyte Reports Third Quarter 2013 Financial Results and Provides Business Update

Endocyte, Inc. (ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced financial results for the third quarter ending Sept. 30, 2013, and provided a business update.

"We made significant progress with our clinical programs during the third quarter and look forward to reporting several important milestones over the next few months," said Ron Ellis, Endocyte's president and chief executive officer. "Enrollment for our Phase 3 PROCEED trial for vintafolide and etarfolatide in platinum resistant ovarian cancer remains on schedule, and we still anticipate an interim analysis at 250 FR(100%) patients during the second quarter of 2014."

Aeterna Zentaris Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) (the "Company") today announced that it has submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency ("AGHD"), with accuracy comparable to available intravenous and intramuscular testing procedures.

David Dodd, President and CEO of Aeterna Zentaris, commented, "The submission of the NDA to the FDA is another major milestone in our strategy to bring macimorelin acetate to market as the first approved oral product for AGHD evaluation.